Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...

Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom ...

USA: Switching to garadacimab may provide a safe and effective option for preventing hereditary angioedema (HAE) attacks, according to interim findings from an ongoing Phase 4 clinical study. Patients ...

Kalbitor (ecallantide) is a medicine used to treat sudden attacks of hereditary angioedema (HAE). During an HAE attack, swelling happens in different areas of the body, such as your face, hands, feet, ...

Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...

Please provide your email address to receive an email when new articles are posted on . The mean attack rate at baseline was 2.18, and this dropped to 0.12 in the open-label extension study. There was ...

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary ...

Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...

Among 100 surveyed U.S. patients with HAE, 89% of whom were on long-term prophylaxis therapies and 11% of whom were on on-demand therapies only, 34% reported having at least one attack per month and ...